Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer

Acta Physiologica

Volumn 187, Issue 4, 2006, Pages 447-457

  Kinnunen, K ^a   Korpisalo, P ^a   Rissanen, T T ^a   Heikura, T ^a   Viita, H ^a   Uusitalo, H ^a   Yla Herttuala S ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adenovirus; Eye; Gene transfer; Neovascularization; Retina; Vascular endothelial growth factor; Vascular leakage

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOPATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARIES; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 33745713181     PISSN: 17481708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2006.01588.x     Document Type: Article

References (33)

1. Adamis, A.P., Shima, D.T., Tolentino, M.J. et al. 1996. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114, 66-71.
2. Aiello, L.P., Pierce, E.A., Foley, E.D. et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92, 10457-10461.
3. Bainbridge, J.W., Mistry, A.R., Thrasher, A.J. & Ali, R.R. 2003. Gene therapy for ocular angiogenesis. Clin Sci (Lond) 104, 561-575.
4. Bressler, N.M. & Bressler, S.B. 1995. Preventative ophthalmology. Age-related macular degeneration. Ophthalmology 102, 1206-1211.
5. Das, A. & McGuire, P.G. 2003. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22, 721-748.
6. Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146, 1029-1039.
7. Eriksson, U. & Alitalo, K. 1999. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 237, 41-57.
8. Ferrara, N. 1999. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237, 1-30.
9. Ferrara, N., Gerber, H.P. & LeCouter, J. 2003. The biology of VEGF and its receptors. Nat Med 9, 669-676.
10. Garner, A. 1994. Vascular diseases. In: A. Garner & G.K. Klintworth (eds) Pathobiology of Ocular Disease: A Dynamic Approach, pp. 1625-1710. Marcel Dekker, New York.
11. Haeseleer, F., Imanishi, Y., Saperstein, D.A. & Palczewski, K. 2001. Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci 42, 3294-3300.
12. Hedman, M., Hartikainen, J., Syvanne, M. et al. 2003. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677-2683.
13. Kaplan, H.J., Leibole, M.A., Tezel, T. & Ferguson, T.A. 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 5, 292-297.
14. Laitinen, M., Makinen, K., Manninen, H. et al. 1998. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9, 1481-1486.
15. Niederkorn, J.Y. 1990. Immune privilege and immune regulation in the eye. Adv Immunol 48, 191-226.
16. Okamoto, N., Tobe, T., Hackett, S.F. et al. 1997. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151, 281-291.
17. Olofsson, B., Korpelainen, E., Pepper, M.S. et al. 1998. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95, 11709-11714.
18. Ozaki, H., Hayashi, H., Vinores, S.A., Moromizato, Y., Campochiaro, P.A., & Oshima, K. 1997. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64, 505-517.
19. Ozaki, H., Seo, M.S., Ozaki, K., et al. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156, 697-707.
20. Penn, J.S., Henry, M.M. & Tolman, B.L. 1994. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36, 724-731.
21. Persico, M.G., Vincenti, V. & DiPalma, T. 1999. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 237, 31-40.
22. Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P. & Smith, L.E. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A, 92, 905-909.
23. Qaum, T., Xu, Q., Joussen, A.M. et al. 2001. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42, 2408-2413.
24. Rahmani, B., Tielsch, J.M., Katz, J. et al. 1996. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 103, 1721-1726.
25. Reich, S.J. & Bennett, J. 2003. Gene therapy for ocular neovascularization: a cure in sight. Curr Opin Genet Dev 13, 317-322.
26. Rissanen, T.T., Markkanen, J.E., Gruchala, M. et al. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92, 1098-1106.
27. Robinson, G.S., Pierce, E.A., Rook, S.L., Foley, E., Webb, R. & Smith, L.E. 1996. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 93, 4851-4856.
28. Ryan, S.J. 1979. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc 77, 707-745.
29. Smith, L.E., Wesolowski, E., McLellan, A. et al. 1994. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35, 101-111.
30. Tobe, T., Okamoto, N., Vinores, M.A. et al. 1998. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 39, 180-188.
31. Tolentino, M.J., McLeod, D.S., Taomoto, M., Otsuji, T., Adamis, A.P. & Lutty, G.A. 2002. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133, 373-385.
32. Witmer, A.N., Vrensen, G.F., Van Noorden, C.J. & Schlingemann, R.O. 2003. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22, 1-29.
33. Yla-Herttuala, S. & Alitalo, K. 2003. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9, 694-701.